ReviewCurrent hypertension reports2020
Fixed-Dose Combination Medications for Treating Hypertension: A Review of Effectiveness, Safety, and Challenges.
Review in Current hypertension reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Economics of Team-Based Care for Blood Pressure Control: Updated Community Guide Systematic Review.American journal of preventive medicine · 2023Pooled it
- Trial
- Bioequivalence and Food Effect Assessment of Two Fixed-Dose Combination Formulations of Telmisartan-Hydrochlorothiazide Tablets in Chinese Healthy Subjects.Clinical and translational science · 2025Trial
- Addressing barriers to using fixed-dose combination antihypertensive medications: lessons from the Million Hearts initiative.Journal of human hypertension · 2026Review
- Medicaid coverage for fixed-dose combination antihypertensive medications - fifty states and Washington, D.C., 2022.Journal of human hypertension · 2026Article
- Drug class duplication patterns among South African middle-aged adults: findings from a medicine claims database.International journal of clinical pharmacy · 2026Article
- Fixed-Dose Combinations for Hypertension: Barriers to Use and Opportunities for Health Systems.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Impact of the 2017 ACC/AHA hypertension guidelines on antihypertensive prescribing in the United States: real-world evidence from a nationally representative population.Frontiers in pharmacology · 2026Article
- Guidance for Prescribing Oral Antihypertensive Medications in the Emergency Department.Current hypertension reports · 2025Review
- Stakeholder Perspectives on a Heart Failure With Reduced Ejection Fraction Polypill: A Multi-Center Mixed Methods Study.Circulation. Cardiovascular quality and outcomes · 2024Article
- The Association Between Type of Insurance Plan, Out-of-Pocket Cost, and Adherence to Antihypertensive Medications in Medicare Supplement Insurance Enrollees.American journal of hypertension · 2024Article
- Facilitators and Barriers of Incremental Innovation by Fixed Dose Combinations in Cardiovascular Diseases.Journal of cardiovascular development and disease · 2024Article
- [Preparation andBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2022Article
- [Control of arterial hypertension: a pending issueControle da hipertensão arterial: um assunto inacabado].Revista panamericana de salud publica = Pan American journal of public health · 2022Article
- [Efficacy of a standardized and simplified strategy for the treatment of high blood pressure in Chile: the HEARTS Initiative in the AmericasEficácia de uma estratégia padronizada e simplificada para o tratamento da hipertensão arterial no Chile: a iniciativa HEARTS nas Américas].Revista panamericana de salud publica = Pan American journal of public health · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo summarize the recent evidence on the effectiveness and safety of antihypertensive fixed-dose combination (FDC) medications, and to describe the facilitators and barriers to implementing FDCs in US clinical practice. RECENT
findingsRecent clinical practice guidelines include FDC use for treating high BP. Clinical trials in recent years support the use of antihypertensive FDCs including low-dose triple- and quadruple-therapy FDCs. Initiating a low-to-standard dose dual-therapy FDCs showed better BP control than initiating treatment with a standard-dose monotherapy, and triple-therapy FDCs produced better BP control rates than dual-therapy FDCs. Retrospective cohort studies showed that FDCs are associated with increased medication adherence, reduced clinical inertia, decreased time to BP control, and improved cardiovascular outcomes. We further discussed barriers and facilitators of wider implementation of antihypertensive FDCs in clinical practice. FDC treatment for hypertension is not commonly used despite historical and recent data which support the effectiveness, safety, and benefits of FDCs. Simplified and protocolized treatment algorithms, team-based care, shared decision-making principles are crucial to successful utilization and implementation of FDC in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.